Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma. - Test2 - elhamkhani - TriplyDB

Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma.

Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma.

http://www.wikidata.org/entity/Q33868508

about

Paving the Road to Tumor Development and Spreading: Myeloid-Derived Suppressor Cells are Ruling the Fate The role of microRNAs in human liver cancers Targeted therapy for hepatocellular carcinoma: novel agents on the horizon Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling Over-expressing the soluble gp130-Fc does not ameliorate methionine and choline deficient diet-induced non alcoholic steatohepatitis in mice.Lack of knowledge: breast cancer and the soluble interleukin-6 receptor.Association between serum interleukin-6 concentrations and mortality in older adults: the Rancho Bernardo study.Thyroid cancer gender disparity.Increased HCMV seroprevalence in patients with hepatocellular carcinoma.Relevance of serum levels of interleukin-6 and syndecan-1 in patients with hepatocellular carcinoma Comprehensive profiling of novel microRNA-9 targets and a tumor suppressor role of microRNA-9 via targeting IGF2BP1 in hepatocellular carcinoma.Interleukin-6-stimulated progranulin expression contributes to the malignancy of hepatocellular carcinoma cells by activating mTOR signaling.Serum Levels of Interleukin-6 and Interleukin-10 as Biomarkers for Hepatocellular Carcinoma in Egyptian Patients.HBV-induced ROS accumulation promotes hepatocarcinogenesis through Snail-mediated epigenetic silencing of SOCS3.Rather than Rs1800796 polymorphism, expression of interleukin-6 is associated with disease progression of chronic HBV infection in a Chinese Han population.Genetically modified animal models recapitulating molecular events altered in human hepatocarcinogenesis.DJ-1 promotes development of DEN-induced hepatocellular carcinoma and proliferation of liver cancer cells.Genetic association of interleukin-6 polymorphism (-174 G/C) with chronic liver diseases and hepatocellular carcinoma Molecular mechanisms of oncogene-induced inflammation and inflammation-sustained oncogene activation in gastrointestinal tumors: an under-appreciated symbiotic relationship.Downregulation of hemojuvelin prevents inhibitory effects of bone morphogenetic proteins on iron metabolism in hepatocellular carcinoma.From physiology to disease and targeted therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis.Fluorescence probes to detect lipid-derived radicals.Susceptibility to hepatocellular carcinoma in the Chinese population--associations with interleukin-6 receptor polymorphism.Serine 727 phosphorylation of STAT3: an early change in mouse hepatocarcinogenesis induced by neonatal treatment with diethylnitrosamine.MicroRNA-125b promotes apoptosis by regulating the expression of Mcl-1, Bcl-w and IL-6R.Adipokines in Liver Cirrhosis.XZH-5 inhibits STAT3 phosphorylation and causes apoptosis in human hepatocellular carcinoma cells.Expression of pro- and anti-inflammatory cytokines in relation to apoptotic genes in Egyptian liver disease patients associated with HCV-genotype-4.Serum IL-6 levels and the risk for hepatocarcinogenesis in chronic hepatitis C patients: an analysis based on gender differences.High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B.Lack of Any Relationship Between Circulating Autoantibodies and Interleukin–6 Levels in Egyptian Patients Infected with the Hepatitis C Virus Unchanged serum viral load and liver function during tocilizumab treatment in a patient with rheumatoid arthritis and hepatitis C virus infection.The Anti-Tumor Effects of M1 Macrophage-Loaded Poly (ethylene glycol) and Gelatin-Based Hydrogels on Hepatocellular Carcinoma.Association of IL-6 polymorphisms with hepatocellular carcinoma risk: evidences from a meta-analysis.IL-6 trans-signaling is essential for the development of hepatocellular carcinoma in mice.Estrogen suppresses metastasis in rat hepatocellular carcinoma through decreasing interleukin-6 and hepatocyte growth factor expression.Evaluation of serum interleukin-6 levels in hepatocellular carcinoma patients: a systematic review and meta-analysis Significance of Heparin-Binding Protein and D-dimers in the Early Diagnosis of Spontaneous Bacterial Peritonitis

P2860

Q26777205-4303F77A-6E1D-4975-B156-74E9E81213C8 Q26861699-CFB67D1A-2F31-4543-8BFF-5B471BA9FBB7 Q27002288-0AA81714-4164-4D15-A346-6D0DF739A697 Q29614596-4BED0586-A0F6-4E4F-95B3-9840749381C4 Q33588191-F19D83C5-C583-4268-A537-15A2548FB702 Q33817373-855AD22A-680A-49B3-AB25-00961F8D7F28 Q34096100-BF0C9B23-88BA-445F-A2F2-62F3F5BA546F Q34238510-6B38501D-6892-47F3-8273-03640B8131CC Q34802748-47D91CC9-A92F-448F-A273-65B352F88D9E Q35574918-BC076B05-7D1D-49AF-9C4A-1FCF5BD97CCE Q35801303-68093F10-F628-4E7D-9A5B-364794D4B2B7 Q36561669-D89DBA5D-EC70-49A3-81F1-717C13E0E5B4 Q36583034-19651149-585B-4019-82E7-C12E79F3330C Q36961950-59EE9D62-68AA-4551-A820-B6C745EE72B2 Q37179313-911FD048-197E-49CD-AB9A-306880CAFF09 Q37382496-7C6C25FB-5CC7-4E2E-92C2-E0DBFD72F5DE Q37452220-3B927718-1640-4CA5-AA98-4D9911670BDF Q37702744-6925FF64-2E95-483A-A0E8-EE3018A706B9 Q38106951-401BA25D-358D-489B-B096-1BA858DC300C Q38211357-4916F693-AAC3-4C08-BAEB-39CC658049EE Q38332451-09A7B88B-5EFE-4FCC-8A37-FF6CDEFC92B3 Q38336406-2C1E69BF-B4B7-4C35-A99B-16B768D68A9D Q38764848-2FC80C33-B45E-47D1-920C-FA2EC02915BF Q39222750-A52BE033-8F21-4192-92CA-50640ADC2A69 Q39293308-206193E1-289B-436E-B724-6FC0C1086538 Q39309630-FD50D31B-C79F-427C-B274-02D1C4494143 Q39404643-C6CF45E9-71EA-477E-AB80-FD198416CD31 Q39594191-24001C54-8704-4A37-A247-22DC104B8B2A Q39624018-92AD55F7-205D-4D43-80AF-5F97597D2659 Q39964655-93EAB2BB-B26C-4CD5-8D79-25B97770CA5C Q39997004-B4F70F68-E152-40E3-BDDD-D8DF591EE802 Q40391710-98AECB26-CC93-4D37-BA33-41373641FE46 Q45364728-50B92AF1-F875-4328-847F-005BE38C5D3B Q45419347-B60DD4D5-5907-4026-A378-E6EB1FB686E5 Q45863467-8DDB347D-EE01-4054-817F-3787C102ADE5 Q51369659-94FF4B9B-6E6D-40F9-B34A-A737AAE92930 Q51507148-0A1AAE0B-B448-4107-AFE4-5E493B52996A Q57494345-0C25DCD7-2840-4944-A190-0F66FC7586EF Q58604321-13DD0C1E-9F71-4CAE-A6C9-9A2D9A087D47

P2860

Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma.

http://www.wikidata.org/entity/Q33868508

description

2006 nî lūn-bûn

@nan

2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Interleukin-6 and its soluble ...... and hepatocellular carcinoma.

@ast

Interleukin-6 and its soluble ...... and hepatocellular carcinoma.

@en

type

label

Interleukin-6 and its soluble ...... and hepatocellular carcinoma.

@ast

Interleukin-6 and its soluble ...... and hepatocellular carcinoma.

@en

prefLabel

Interleukin-6 and its soluble ...... and hepatocellular carcinoma.

@ast

Interleukin-6 and its soluble ...... and hepatocellular carcinoma.

@en

P1433

Q33868508-377B5AC4-7C36-471D-B50E-AC8EE453E865

P1476

Q33868508-170B5374-BD94-42B5-9888-F520771ED347

P2093

Q33868508-008D4279-071D-4B26-A22E-351FFB232D9C

Q33868508-01C6DF22-089F-4640-BBD5-2A365020CB67

Q33868508-4FC8A0E8-5F7C-472E-94F4-90EBBD8F2A56

Q33868508-5C849789-54F1-47BB-BA46-DFC2023A412F

Q33868508-878D6292-8480-467F-9D00-6712433F69C7

Q33868508-97F8538E-112B-4BC7-8499-1FAEE31E38AD

Q33868508-E0B0D756-F0C2-42CD-AC17-1E421D682706

P2860

Q33868508-06DA7560-CA52-4AC4-98BE-BB551A72B749

Q33868508-18A54936-61BB-4885-B7F3-63B3E60F2387

Q33868508-1B9AB575-3E1F-4596-B6DC-EBF87560CA28

Q33868508-25F46E79-BBA5-4E1F-9125-4B56ACDE79A8

Q33868508-3BD7D101-32E4-4BE7-AD72-37BC8CD19363

Q33868508-3DC2B43F-FF6A-4A81-97C2-43F894FD61A4

Q33868508-4158A0BB-BF6A-40CC-A23A-87C8476E4DC5

Q33868508-5829E594-0D7D-42D0-AADB-D73489C87287

Q33868508-6F561F5D-FB28-46D9-9D39-17E4D044273F

Q33868508-718AD13E-5E02-4D82-A673-CA5259ABC625

P304

Q33868508-9315A243-532E-4974-BB59-CCBA8E479798

P31

Q33868508-099489C0-6C9C-4B30-89D0-BA9177458AE4

P356

Q33868508-BB1AC5F5-C2E1-4055-921B-64A0AB3B6B44

P407

Q33868508-E1F7F4C5-64E6-486D-BF32-8BE4FED58B4E

P433

Q33868508-29AA22A8-5F0C-49F8-9C46-EC5F5ECCE84D

P478

Q33868508-FF55C772-4D99-4BEC-8E3A-EFB55892DD8E

P50

Q33868508-83B7A569-6652-4E59-9E6A-39EDCBBA7B45

Q33868508-D874EA93-A238-43A7-9F29-AE7DAE2C3074

P577

Q33868508-F76289A5-EFD4-49B4-999C-E3AD1BCBD4D1

P698

Q33868508-912ED291-83A9-4809-9C0A-7F360C25B603

P921

Q33868508-0A12A22C-EAA2-4380-B7C3-50CDE5CD30E3

Q33868508-55711fca-d407-46bb-b322-769e9f0468bd

P932

Q33868508-B840C082-3C3F-4492-8C38-4F6DE8DC982A

P356

WJG.V12.I16.2563

P1433

World Journal of Gastroenterology

P1476

Interleukin-6 and its soluble ...... and hepatocellular carcinoma.

@en

P2093

Ada-Maria Florena

http://www.w3.org/2001/XMLSchema#string

Angela Terranova

http://www.w3.org/2001/XMLSchema#string

Emanuele La Spada

http://www.w3.org/2001/XMLSchema#string

Fabio D'Antona

http://www.w3.org/2001/XMLSchema#string

Lydia Giannitrapani

http://www.w3.org/2001/XMLSchema#string

Maurizio Soresi

http://www.w3.org/2001/XMLSchema#string

Natale D'Alessandro

http://www.w3.org/2001/XMLSchema#string

P2860

Interleukin-6 family of cytokines and gp130

Coexpression of IL-6 and soluble IL-6R causes nodular regenerative hyperplasia and adenomas of the liver.

Impairment of natural killer functions by interleukin 6 increases lymphoblastoid cell tumorigenicity in athymic mice.

Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias

Serum levels of interleukin 6 in patients with lung cancer.

Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression.

Molecular regulation of B lymphocyte response.

Interleukin-6 in renal cell carcinoma.

Inhibition of growth of human hepatoma cells by dual-function antisense IL-6 oligonucleotides.

Blocking signaling through the Gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to etoposide and cisplatin-mediated cytotoxicity.

P304

2563-2568

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3748/WJG.V12.I16.2563

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Giuseppe Montalto

Melchiorre Cervello

P577

2006-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16688802

http://www.w3.org/2001/XMLSchema#string

P921

liver cirrhosis

P932

4087989

http://www.w3.org/2001/XMLSchema#string